OSI-7836 Uses, Dosage, Side Effects and more
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested. This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents.
| Trade Name | OSI-7836 |
| Generic | OSI-7836 |
| Type | |
| Formula | C9H14ClN3O5S |
| Weight | Average: 311.743 Monoisotopic: 311.03426897 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in solid tumors.
How OSI-7836 works
OSI-7836 appears to have a different mechanism of tumor growth inhibition blocking the cell division cycle at a different point (the G2 phase) than gemcitabine. The mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell death.
